Openbookopenbook
Equity
LianBio(LIANY)
USD --+0.00%
Reward70High
Risk33Moderate
📊75%Data
LIANY
+0.0 · +0.00%
USD · PINK
LianBio | Healthcare
Quality Compounder
Market Cap:9.93M
ℹ️
Reward Rating
70
High
Top 25% (model universe)
75% data coverage
ℹ️
Risk Rating
33
Moderate
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on LIANY to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

Analyst Target

Analyst consensus price target: $4.80.

What is LianBio?

LianBio, operates as a biotechnology company in China and other Asian countries.

LIANY · Verdict

Strong reward · moderate risk

LIANY scores well on balance sheet and growth with no major weaknesses flagged in the model.

Based on 88% data coverage

LIANY · Verdict

What’s working & what to watch

Strengths 5

  • Balance sheet86/100

    Current ratio 74.19

  • Growth85/100

    Top decile vs peers

  • Volatility80/100

    Top decile vs peers

  • Valuation75/100

    Above average

  • Profitability65/100

    -32% return on equity

No major weaknesses flagged.

Model-based scoring. For information only — not financial advice.

What is LianBio?

LianBio, operates as a biotechnology company in China and other Asian countries. It offers medicines for cardiovascular, oncology, ophthalmology, and inflammatory disease indications. The company is listed on the PINK in USA, operating in the Healthcare sector, with a market capitalisation of 9.93M.

Financial Highlights

Investment Breakdown

📈 Growth
Revenue and earnings growing steadily, indicating improving operating performance.
💰 Profitability
Adequate profitability with some margin variability in recent periods.
⚠️ Risk
Below-average volatility supports a steadier risk profile.
💸 Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: High (70)

The scoring profile indicates a strong reward potential, driven primarily by growth and valuation. Risk indicators are moderate, consistent with typical market exposure.

For informational purposes only. Not financial advice.

Company Information
SectorHealthcare
Market Cap9.93M
P/E RatioN/A
Dividend YieldN/A
52 Week High0.439
52 Week Low0.03
Last AnnualSeptember
IPO Date11/1/2021
IncorporatedUSA
Shares Outstanding109M
No. of Employees163
IndustryBiotechnology
ExchangePINK
Beta0.417
CurrencyUSD
Websitewww.lianbio.com
openbook

Stock research for everyday UK investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.